Update shared on 29 Nov 2025
Analysts have reduced their price targets for DSM-Firmenich by notable amounts, with recent estimates moving downward. Concerns about increased competition and pricing pressure are weighing on sentiment.
Analyst Commentary
Recent street research highlights a split in sentiment regarding DSM-Firmenich's outlook. While several analysts remain constructive on the company’s prospects and maintain positive ratings, concerns over competition and pricing pressure have driven a series of downward price target revisions. Below are the main arguments observed from both bullish and bearish analysts:
Bullish Takeaways- Bullish analysts continue to maintain Buy or Overweight ratings despite recent price target cuts. This reflects confidence in the company’s long-term growth potential.
- The company is regarded as well-positioned to capitalize on structural demand in consumer ingredients and nutrition markets. This positioning could support its valuation over time.
- Some price targets, although reduced, remain significantly above the current share price. This implies potential upside if execution improves and competitive headwinds diminish.
- DSM-Firmenich’s focus on innovation and its diversified product portfolio are seen as strengths. These factors could help mitigate the impact of short-term market volatility.
- Bearish analysts highlight growing commoditization risks in European consumer ingredients, particularly in light of increased competition from Chinese firms and sustained pricing pressure.
- Multiple downward revisions of price targets suggest that near-term execution challenges and margin pressure remain top concerns.
- The most pessimistic valuations have emerged from analysts who rate the shares as Underweight. These analysts set price targets significantly below those of their bullish peers.
- Uncertainties about DSM-Firmenich’s ability to defend its market share and maintain premium pricing are weighing negatively on consensus expectations.
What's in the News
- Citi has lowered its price target on DSM-Firmenich to EUR 110 from EUR 127 while maintaining a Buy rating on the shares (Citi).
Valuation Changes
- Fair Value Estimate remains unchanged at €102, reflecting analyst consensus on the company’s intrinsic valuation.
- Discount Rate has risen slightly to 6.09 percent from 6.07 percent. This indicates a marginal increase in perceived risk or cost of capital.
- Revenue Growth projections have edged down modestly to 1.69 percent from 1.70 percent. This signals a minor adjustment in expectations for topline expansion.
- Net Profit Margin estimates have increased incrementally to 8.45 percent from 8.45 percent. This suggests slightly improved expectations on profitability.
- Future P/E ratio forecasts have remained steady, ticking up only marginally to 27.50x from 27.48x. This shows little change in anticipated valuation multiples.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.